- 75.6k views
Dapagliflozin in patients with Chronic Kidney Disease
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
About the Speaker
Dr Satyanarayana Garre
Consultant Nephrologist, Apollo Hospitals, Hyderabad
Upcoming Case Discussions
Treatment of Renal Disease in ANCA Vasculitis
The treatment of renal disease in ANCA-associated vasculitis (AAV) typically involves a combination of immunosuppressive therapies to control inflammation and prevent further kidney damage. First-line treatment often includes high-dose corticosteroids and cyclophosphamide or rituximab, both of which help to induce remission by targeting the underlying immune system dysfunction. In cases of kidney failure or rapidly progressive glomerulonephritis, plasmapheresis may be used to remove circulating autoantibodies. Once remission is achieved, maintenance therapy with lower doses of immunosuppressants, such as azathioprine or mycophenolate mofetil, is used to prevent relapses and preserve kidney function.
Management of Pediatric Type 1 Diabetes
Pediatric type 1 diabetes management focuses on maintaining glycemic control while supporting normal growth. Insulin therapy, via multiple daily injections or pumps, is essential, with doses adjusted based on blood glucose monitoring or continuous glucose monitoring (CGM). Nutrition plans emphasizing carbohydrate counting and balanced meals are crucial, alongside adjustments for physical activity to prevent glucose fluctuations. Education for families on recognizing hypo- and hyperglycemia symptoms and managing sick days is vital. Regular follow-ups with a pediatric endocrinologist help monitor HbA1c levels, growth, and complications. Psychosocial support is key for ensuring adherence and addressing emotional challenges.
Rising Cardiac Arrests in Young Entrepreneurs
The increasing cases of cardiac arrests among young entrepreneurs are becoming a serious health concern. Intense stress, long working hours, unhealthy eating habits, and lack of physical activity are major contributors to heart-related issues in this group. This often leads to neglecting personal health, resulting in irregular sleep patterns and chronic fatigue. Additionally, skipping regular medical check-ups can leave underlying heart conditions undetected. Emphasizing stress management, healthy lifestyle choices, and routine health screenings is crucial to reducing this growing risk
Medical Management of Endometriosis
Medical management of endometriosis typically involves the use of hormonal therapies such as birth control pills, progestins, or GnRH agonists to reduce estrogen levels and suppress the growth of endometrial tissue. Pain management with NSAIDs, as well as targeted treatments like aromatase inhibitors or the use of intrauterine devices (IUDs), can help alleviate symptoms. In some cases, additional treatments like surgery may be considered for severe cases or when fertility is a concern.
Analytical Skills in Problem Solving
Today’s session on analytical tools and techniques in healthcare can provide valuable insights into how data-driven approaches enhance decision-making and problem-solving. Sharing personal or professional experiences where analytical skills were effectively used to address challenges can offer practical understanding and inspire learners. These skills are crucial in healthcare for accurate patient diagnosis, effective treatment planning, and efficient resource allocation. By applying analytical methods, healthcare professionals can improve patient outcomes, streamline operations, and make informed, evidence-based decisions that contribute to overall healthcare efficiency and quality.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr Satyanarayana Garre's Talks on Assimilate
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.